KOD (Kodiak Sciences) Ending Cash Position: $175.71 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KOD Kodiak Sciences Inc KOD
27 GF Score
Price $41.38
! 4 Warning Signs
View Full Analysis

What is Kodiak Sciences Ending Cash Position?

Kodiak Sciences KOD -0.50% 27 Ending Cash Position is $175.71 Mil as of Mar. 2026. GuruFocus rates KOD with a GF Score™ of 27/100. The stock has 4 warning signs investors should review.

Kodiak Sciences's Ending Cash Position for the quarter that ended in Mar. 2026 was $175.71 Mil.

Kodiak Sciences's quarterly Ending Cash Position increased from Sep. 2025 ($78.22 Mil) to Dec. 2025 ($216.05 Mil) but then declined from Dec. 2025 ($216.05 Mil) to Mar. 2026 ($175.71 Mil).

Kodiak Sciences's annual Ending Cash Position declined from Dec. 2023 ($291.83 Mil) to Dec. 2024 ($174.26 Mil) but then increased from Dec. 2024 ($174.26 Mil) to Dec. 2025 ($216.05 Mil).

Kodiak Sciences Ending Cash Position Related Terms

Kodiak Sciences Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Kodiak Sciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kodiak Sciences Ending Cash Position Chart

Kodiak Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 737.83 196.76 291.83 174.26 216.05

Kodiak Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 145.04 110.35 78.22 216.05 175.71
KOD
27GF Score
Kodiak Sciences Inc KOD
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kodiak Sciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Kodiak Sciences's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=174.258+41.788
=216.05

Kodiak Sciences's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=216.046+-40.332
=175.71

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $175.71 Mil mean?
Kodiak Sciences (KOD) has a Ending Cash Position of $175.71 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Kodiak Sciences and its competitors.
Is Kodiak Sciences' Ending Cash Position too high?
Kodiak Sciences' current Ending Cash Position is $175.71 Mil. Overall, Kodiak Sciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Kodiak Sciences' Ending Cash Position compare to BEAM and TARS?
Kodiak Sciences' Ending Cash Position of $175.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Kodiak Sciences and its competitors. Kodiak Sciences's current Ending Cash Position is $175.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kodiak Sciences stock overvalued right now?
Kodiak Sciences (KOD) has a current Ending Cash Position of $175.71 Mil. The current Ending Cash Position is $175.71 Mil. Kodiak Sciences' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Kodiak Sciences (KOD), the current Ending Cash Position is $175.71 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kodiak Sciences Business Description

Other Exchanges K27:Germany
Address 1250 Page Mill Road, Palo Alto, CA, USA, 94304
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
27GF Score

Get the complete analysis for KOD

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.38
Price